Richtlijn: Gezonde slaap en slaapproblemen bij kinderen (2017)


1. Bruni O, Alonso-Alconada D, Besag F, et al. Current role of melatonin in pediatric neurology: Clinical recommendations. Eur J Paediatr Neurol. 2015;19(2):122-133.

2. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: A bayesian meta-analysis. J Clin Psychopharmacol. 2012;32(3):309-316.

3. Owens JA, Moturi S. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009;18(4):1001-1016.

4. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention deficit/hyperactivity disorder in children and adolescents--meta-analysis and meta-regression analysis. Psychopharmacology (Berl ). Oct 2007;194(2):197-209.

5. Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: Current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227-246.

6. Fietta P, Fietta P, Delsante G. Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci. Oct 2009;63(5):613-622.

7. Fernandez-San-Martin MI, Masa-Font R, Palacios-Soler L, Sancho-Gomez P, Calbo-Caldentey C, Flores-Mateo G. Effectiveness of valerian on insomnia: A meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010;11(6):505-511.

8. Owens JA, Babcock D, Blumer J, et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: Rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005;1(1):49-59.

Pagina als PDF